T-Cypher Bio ("T-Cypher), a biotechnology company developing novel T cell receptor (TCR)-based T cell engagers that target high copy number antigens, today announced its relocation to Abingdon Science Park, Oxford, UK.
https://www.news-medical.net/news/20261111/T-Cypher-Bio-extends-footprint-in-purpose-built-laboratory-space-at-Abingdon-Science-Park-Oxford.aspx